Oxford-based Immunocore has so far concentrated on developing its T-cell receptor medicines to fight cancer, where it has collaborations with Roche (>> Roche Holding Ltd.), GlaxoSmithKline (>> GlaxoSmithKline), AstraZeneca (>> AstraZeneca) and Eli Lilly (>> Eli Lilly and Company).

The tie-up with the Gates Foundation will extend the work into finding and developing new treatments for tuberculosis, HIV and other infectious diseases.

(Reporting by Ben Hirschler; Editing by Mark Potter)